Screener
Syndax Pharmaceuticals SNDX Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 3,561 | 7,183 |
| Other expense | (186) | (221) |
| Total other (expense) income, net | (8,471) | (1,089) |
| Net loss | $(42,673) | $(84,846) |
| Other Comprehensive loss: | ||
| Unrealized (loss) gain on marketable securities | (441) | 364 |
| Other Comprehensive loss | (43,114) | (84,482) |
| Net loss per share: |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's business segments — net income loss?
- Syndax Pharmaceuticals (SNDX) reported business segments — net income loss of -$42.67M in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — net income loss changed year-over-year?
- Syndax Pharmaceuticals's business segments — net income loss increased by 49.7% year-over-year, from -$84.85M to -$42.67M.
- What is the long-term trend for Syndax Pharmaceuticals's business segments — net income loss?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — net income loss has grown at a 24.1% compound annual growth rate (CAGR), from -$149.34M to -$285.42M.
- What does business segments — net income loss mean?
- This metric represents the total profit or loss generated by the business segment after accounting for all revenues, operating expenses, research and development costs, and other non-operating items. It serves as the primary indicator of the segment's financial viability and its ability to generate sustainable returns from its therapeutic pipeline. For clinical-stage companies, this figure highlights the burn rate and the financial efficiency of the segment's drug development programs.
Ask your AI about Syndax Pharmaceuticals's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude